News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 3, 2022-Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022-
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Feb 22, 2022
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Nov 10, 2021
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Nov 3, 2021-Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of September 30, 2021-
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Sep 27, 2021
Tyra is striving to excel in three areas: crystallography, cell-based assays and in-vivo models CEO: Todd Harris Based: Carlsbad, California Founded: 2018 Clinical focus: Overcoming acquired drug...
-
Sep 17, 2021
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Sep 14, 2021
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Mar 31, 2021– Financing led by Nextech Invest with participation from Cormorant Asset Management, BVF Partners, L.P., Janus Henderson Investors, and Logos, along with existing investors Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan
CARLSBAD, Calif., Mar. 31, 2021 — Tyra Biosciences, a biotech company targeting acquired resistance in oncology with purpose-built drugs, today announced the closing of a $106 million Series B...
-
Jan 10, 2020– Round co-led by Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan, representing a group of seasoned early-stage and crossover investors
CARLSBAD, Calif., Jan. 10, 2020 — Today Tyra Biosciences announced a Series A financing of $50M to discover and develop new small molecule therapies targeting acquired resistance in oncology....